Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.

Journal of clinical pharmacy and therapeutics - 1 Aug 2014

Garcés-Eisele S J, Cedillo-Carvallo B, Reyes-Núñez V, Estrada-Marín L, Vázquez-Pérez R, Juárez-Calderón M, Guzmán-García M O, Dueñas-González A, Ruiz-Argüelles A

Abstract excerpt

WHAT IS KNOWN AND OBJECTIVE: Hydralazine is an inhibitor of DNA methyltransferases, whereas valproate interferes with histone deacetylation. In combination, they show a marked synergism in reducing tumour growth as well as development of metastasis and inducing cell differentiation. Hydralazine is metabolized by the highly polymorphic N-acetyltransferase 2. The current pilot study was performed to analyse the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Arylamine N-Acetyltransferase

Share to Chromatography, High Pressure Liquid

Share to Mexico

Share to Pilot Projects

Share to Tandem Mass Spectrometry

Share to Valproic Acid

Source

Identifiers

PMID: 24702251
DOI: 10.1111/jcpt.12155

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.PMID 24702251Read ↗

N-Acetyltransferase 2 Genotype-Dependent N-Acetylation of Hydralazine in Human Hepatocytes.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.Semantic proximity Read ↗

Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.Semantic proximity Read ↗

Mesalazine pharmacokinetics and NAT2 phenotype.Semantic proximity Read ↗

Genotype-Guided Hydralazine TherapySemantic proximity Read ↗

Global population frequencies of <i>NAT2</i> star alleles observed in three large biobanksSemantic proximity Read ↗

Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.Semantic proximity Read ↗

Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs.Semantic proximity Read ↗

Acetylation phenotype in hypertensive patients.Semantic proximity Read ↗

Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.Semantic proximity Read ↗

Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.Semantic proximity Read ↗

Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.